royal research semaglutide Oral Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients GLP-1 Semaglutide

From combination therapies that preserve muscle mass, to oral agents breaking bioavailability barriers, and dual-agonists redefining treatment strategieseach advancement marks a critical step forward for the millions living with obesity and type 2 diabetes

However, the reduction in HF hospitalisations with semaglutide did not reach statistical significance

Zhang J, Zhang F, Ge J (2022) SGLT2 inhibitors protect cardiomyocytes from myocardial infarction: a direct mechanism

Success requires more than medication alone-commitment to dietary improvements, increased activity, and behavioral changes significantly impacts outcomes

Perfect for older adults and those with digestive concerns